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RISK FACTORS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN
PATIENTS WITH MYELOFIBROSIS WITH MYELOID METAPLASIA
Baurmann, H.1, Collenbusch, F.1, Schmid, C.2, Finke, J.3, Stadler, M.4,
Bornhaeuser, M.5, Schleuning, M.1, Schwerdtfeger, R.1. 1Deutsche
Klinik fuer Diagnostik, Wiesbaden, Germany; 2University of Munich,
Munich, Germany; 3University of Freiburg, Freiburg, Germany; 4Uni-
versity of Hannover, Hannover, Germany; 5University of Dresden,
Dresden, Germany.
Objective: We sought to determine risk factors for allogeneic
stem cell transplantation in myelofibrosis with myeloid metaplasia
(MMM) by retrospective analysis within the German Cooperative
Transplant Group. Patients: Between 1999 and 2006 97 patients
(pts) from 15 German centers with an median (md) age of 51 (19–
66) years were grafted from 41 related and 56 unrelated donors.
74 pts had chronic idiopathic myelofibrosis, 13 and 10 pts MMM
secondary to ET and PV, respectively (resp.). 32 pts were Dupriez
score 0, 37 score 1 and 28 score 2 at transplant, 49 needed red cell
transfusions. Chromosomal and molecular analysis was available
from 75 and 51 pts resp.: 51 pts had favourable, 24 pts unfavourable
cytogenetics, 31 pts were JAK2 mutated. Conditioning was of stan-
dard, intermediate and reduced intensity in 27, 57 and 13 cases. 28
pts received bone marrow, 69 PBSC. Cellular immunotherapy (5
boosts, 16 donor lymphocytes) was given in 19 cases for 16 relapses,
2 incomplete chimerisms and one graft failure.Results:At amd fol-
low up of 975 (100–2630) days probability of overall and relapse free
survival (OS and RFS) was 62 and 39%. Neither time from diagno-
sis to transplant, age, B-symptoms, marrow fibrosis, splenomegaly,
JAK2, hemoglobin\10 g/dl, platelets\100/nl, LDH, comorbidity
(CCI or HCT-CI), conditioning, type of donor nor graft source
were discriminative for survival. Log rank test showed a trend to-
wards lower survival in cases with Dupriez score $1 (p 5 0.07)
and transfusion dependence (p 5 0.1). Solely pretransplant new
Mayo PSS (p5 0.019), circulating blasts .1% (p5 0.016), mono-
cytes .1/nl (p 5 0.008) and cytogenetics (p 5 0.009) were predic-
tive for survival after allogeneic transplant. Cox regression analysis
within pretransplant variables revealed cytogenetics as the only in-
dependent factor for OS and RFS (p5 0.023). Following transplant
acute GvHD#II was associated with better RFS than aGvHDIII-
IV (49 versus 19%, p\ 0.0001). Limited chronic GvHD led to an
identical OS and RFS of 84 and 81% as opposed to 43%RFS for no
and 20% RFS for extensive cGvHD, resp. (p5 0.018). 7 pts treated
with cellular immunotherapy had a partial and 7 a complete re-
sponse. Conclusions: Pretransplant disease characteristics like cy-
togenetics are the most important outcome variables for
allogeneic stem cell transplantation inMMM.Evidence for a potent
graft-versus-myelofibrosis-effect suggests exploitation of adjuvant
donor lymphocyte infusions to improve these results.
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LONG-TERM FOLLOW-UP OF ADMINISTRATION OF DONOR-DERIVED
EBV-SPECIFIC CTLS TO PREVENT AND TREAT EBV LYMPHOMA AFTER
HEMOPOIETIC STEM CELL TRANSPLANT
Hale, G.A.1, Pule, M.2, Amrolia, P.3, Weiss, H.2, Bollard, C.2,
Rochester, R.1, Brenner, M.2, Rooney, C.2, Heslop, H.2. 1St. Jude Chil-
dren’s Research Hospital, Memphis, TN; 2Baylor College of Medicine,
Houston, TX; 3Great Ormond Street Hospital for Children, London,
United Kingdom.
Since 1993 we have administered polyclonal donor-derived EBV-
specific CTLs to high-risk recipients after HSCT. A total of 73 pa-
tients have received CTLs, 66 as prophylaxis and 7 as therapy. 11patients had underlying primary immunodeficiencies (6 XLP, 1
WAS, 2 undefined CID, 2 CAEBV), and 5 had developed EBV-as-
sociated LPD or HLHwhich was controlled prior to HSCT. None
of the patients on the prophylaxis study had any acute toxicity and
only 2 patients developed exacerbations of previously existing
GVHD month after infusion. Local inflammation during a thera-
peutic response was seen in 3 patients who had high EBV DNA
and likely had undiagnosed LPD prior to receiving CTLs. All re-
covered with no active intervention and had no long term sequelae.
6 patients have been treated for established EBV lymphoma, with
complete responses seen in 5, accompanied by accumulation of
gene-marked CTL at sites of disease. In 1 patient with extensive dis-
ease significant inflammation was seen at sites of disease after CTL
administration illustrating the benefits of treating patients with
early disease. The patient who failed treatment was found to have
a mutation resulting in deletion of the two 2 immunodominant
HLA11 restricted epitopes in EBNA 3B, recognized by the donor
CTL line. In the first 26 patients CTLs were marked with the neo-
mycin resistance gene to track their fate and persistence and 17 of
these 26 patients are alive from 11 to 14 years post CTLs with the
remaining 9 patients dying from relapse (n 5 6) infection (n 5 2)
and a motor vehicle accident (n 5 1). No RCR has been detected
and no patient has developed any new malignancies although 1 pa-
tient had recurrence of a pre-existing non hematologic malignancy
which was negative for themarker gene by PCR analysis. Analysis of
DNA using a real time PCR assay has shown detection of the
marker gene for up to 85 months with intermittent detection in pe-
ripheral blood T-cells. The gene-modified EBV-CTL population
expanded in vivo directly after infusion and also at later times in re-
sponse to EBV-reactivation, contracting when the antigenic stimu-
lus subsided. Integration site analysis performed on peripheral
blood samples has shown polyclonal cell populations with no gene
or genomic locus appearing to be preferentially selected by retrovi-
ral integration. EBV-specific CTLs can therefore restore anti-viral
immunity and mediate antitumor effects with an excellent safety
profile on long term follow up.
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A MULTICENTRIC COMPARATIVE ANALYSIS OF OUTCOMES OF HLA
IDENTICAL RELATED CORD BLOOD AND BONE MARROW TRANSPLAN-
TATION IN PATIENTS WITH BETA-THALASSEMIA OR SICKLE CELL
DISEASE
Kabbara, N.1, Locatelli, F.2, Rocha, V.1, Ghavamzadeh, A.3,
Bernaudin, F.4, Li, C.-K.5, Vermylen, C.6, Stein, J.7, Beruchel, A.8,
Cordonnier, C.9, Roberts, I.10, Socie, G.11, Gluckman, E.1, Walters, M.12.
1Eurocord, Paris, France; 2 IRCCS Policlinico San Matteo, Pavia, Italy;
3Shariati Hospital, Teheran, Islamic Republic of Iran; 4Intercommunal
Hospital, Creteil, France; 5Prince of Wales Hospital, Shatin, Hong Kong;
6Cliniques Universitaires St-Luc, Brussels, Belgium; 7Schneider Children’s
Medical Center, Petach-Tikva, Israel; 8Robert-Debre Hospital, Paris,
France; 9HenriMondorHospital, Paris, France; 10HammersmithHospital,
London, United Kingdom; 11St-Louis Hospital, Paris, France; 12Children’s
Hospital and Research Center, Oakland, CA.
Most patients with beta thalassemia major (TM) or sickle cell dis-
ease (SCD) can be cured by hematopoietic stem cell transplantation
(HSCT) from either cord blood (CB) or bone marrow (BM). One
advantage of CB is the absence of risk associated with donation.
In order to compare outcomes after HSCT with CB or BM, we
studied 402 patients with TM or SCD who received HLA identical
sibling CB (n 5 72) or BM (n 5 330) allografts between 1994 and
2005. In order to avoid center and period effect, only centers that
performed both types of HSCT during the same period were3
4 CIBMTR Best Abstract Awards for Clinical Researchincluded. We compared the incidence of hematopoietic recovery,
acute and chronic graft-versus-host disease (GvHD), survival and
disease-free survival (DFS) after CB and BM transplantation. Com-
pared to BM, CB recipients were significantly younger (median of
5.5 y versus 7.6 y), smaller (18 kg vs 26 kg), and were transplanted
more recently (in 2000 vs 1998). In the BM group, there were 146
(44%) SCD and 184 (56%) TM patients, and in the CB group, 24
(33%) SCD and 48 (67%) TM patients. The indications for trans-
plantation in SCD were not statistically different between CB and
BM groups, however, more TM patients belonging to Pesaro II-
III risk classes received BM (64%) compared to CB (36%) (p 5
0.04). There were also differences in the conditioning regimen
(more frequent use of ATG/ALG in BM group and of Fludarabine
in the CB group) and GVHDprophylaxis (more methotrexate-con-
taining therapy in BM compared to CB). Moreover, the nucleated
cell content was 10 times higher in BM compared to CB. The table
below shows the non-adjusted univariate analysis for outcomes for
all patients according to the stem cell source used. After HSCT
for TM, the 5 year-DFS rates were 88% and 83% for BM and
CB recipients respectively, and after HSCT for SCD, 94% and
96% respectively. In a multivariate analysis adjusted for age andtype of hemoglobinopathy, DFS was not statistically different be-
tween CB and BM recipients (RR5 1.64, p5 0.20). In conclusion,
patients with TM or SCD had excellent outcomes after HSCT
whether they received CB or BM from an HLA identical sibling.
These results strongly suggest that CB transplantation from HLA
identical siblings should be pursued when possible to avoid the dis-
comfort and risks of a bone marrow harvest.
Non-adjusted univariate analysis of outcomes for all patients (TM and
SCD) after HLA-identical related HSCT according to the stem cell source
used
Source
Neutrophil
recovery
Acute
GvHD
Chronic
GVHD
5 y
survival
5 y
DFS
CB 90 ± 4% 9 ± 4% 7 ± 4% 95 ± 3% 86 ± 5%
BM 94 ± 2% 10 ± 3% 5 ± 2% 96 ± 2% 91 ± 3%
p value 0,01 0,81 0,53 0,83 0,28
